{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:32:54Z","timestamp":1792758774931,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41434-025-00545-6","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T21:10:10Z","timestamp":1750281010000},"page":"594-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thrombotic microangiopathy following gene therapy for 5q-spinal muscular atrophy"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-8027","authenticated-orcid":false,"given":"Clara Gontijo","family":"Camelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Holanda","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane Ara\u00fajo Martins","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Caires Oliveira Achili","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Banzzatto","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejane Souza Macedo","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Spinola Costa","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Gurgel-Giannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaina Monteiro","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana Maria Carvalho","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmar","family":"Zanoteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"545_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365.","journal-title":"Cell"},{"key":"545_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83:810\u20137.","journal-title":"Neurology"},{"key":"545_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82:883\u201391.","journal-title":"Ann Neurol"},{"key":"545_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet 2012;20:27\u201332.","journal-title":"Eur J Hum Genet"},{"key":"545_CR5","first-page":"1","volume":"82","author":"E Zanoteli","year":"2024","unstructured":"Zanoteli E, Araujo A, Becker MM, Fortes C, Franca MC Jr, et al. Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy. Arq Neuropsiquiatr. 2024;82:1\u201318.","journal-title":"Arq Neuropsiquiatr"},{"key":"545_CR6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","volume":"36","author":"HA Blair","year":"2022","unstructured":"Blair HA. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy. CNS Drugs. 2022;36:995\u20131005.","journal-title":"CNS Drugs"},{"key":"545_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"545_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100817","volume":"37","author":"V Gowda","year":"2024","unstructured":"Gowda V, Atherton M, Murugan A, Servais L, Sheehan J, Standing E, et al. Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom. Lancet Reg Health Eur. 2024;37:100817.","journal-title":"Lancet Reg Health Eur"},{"key":"545_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jpc.16340","volume":"59","author":"D Yang","year":"2023","unstructured":"Yang D, Ruan Y, Chen Y. Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis. J Paediatr Child Health. 2023;59:431\u20138.","journal-title":"J Paediatr Child Health"},{"key":"545_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"DH Chand","year":"2021","unstructured":"Chand DH, Zaidman C, Arya K, Millner R, Farrar MA, Mackie FE, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2021;231:265\u20138.","journal-title":"J Pediatr"},{"key":"545_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","volume":"225","author":"AG Feldman","year":"2020","unstructured":"Feldman AG, Parsons JA, Dutmer CM, Veerapandiyan A, Hafberg E, Maloney N, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225:252\u20138.e1.","journal-title":"J Pediatr"},{"key":"545_CR12","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou J, de Pellegars A, Porcheret F, Fremeaux-Bacchi V, Allain-Launay E, Debord C, et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 2022;6:4266\u201370.","journal-title":"Blood Adv"},{"key":"545_CR13","doi-asserted-by":"crossref","unstructured":"Mendon\u00e7a RH, Ortega AB, Matsui C Jr, van der Linden V, Kerstenetzky M, et al. Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort. Gene Ther. 2024;31:391\u20139.","DOI":"10.1038\/s41434-024-00456-y"},{"key":"545_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","volume":"44","author":"JW Day","year":"2021","unstructured":"Day JW, Mendell JR, Mercuri E, Finkel RS, Strauss KA, Kleyn A, et al. Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug Saf. 2021;44:1109\u201319.","journal-title":"Drug Saf"},{"key":"545_CR15","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.ekir.2024.05.016","volume":"9","author":"M Urra","year":"2024","unstructured":"Urra M, Lyons S, Teodosiu CG, Burwick R, Java A. Thrombotic microangiopathy in pregnancy: current understanding and management strategies. Kidney Int Rep. 2024;9:2353\u201371.","journal-title":"Kidney Int Rep."},{"key":"545_CR16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.ekir.2024.04.024","volume":"9","author":"N Schwotzer","year":"2024","unstructured":"Schwotzer N, El Sissy C, Desguerre I, Fremeaux-Bacchi V, Servais L, Fakhouri F. Thrombotic microangiopathy as an emerging complication of viral vector-based gene therapy. Kidney Int Rep. 2024;9:1995\u20132005.","journal-title":"Kidney Int Rep."},{"key":"545_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125:616\u20138.","journal-title":"Blood"},{"key":"545_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","volume":"6","author":"LMP Palma","year":"2021","unstructured":"Palma LMP, Sridharan M, Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep. 2021;6:11\u201323.","journal-title":"Kidney Int Rep."},{"key":"545_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15:312\u201322.","journal-title":"J Thromb Haemost"},{"key":"545_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"545_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1088031","volume":"13","author":"T Mazzierli","year":"2022","unstructured":"Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management. Front Pharm. 2022;13:1088031.","journal-title":"Front Pharm"},{"key":"545_CR22","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s00467-021-05370-8","volume":"37","author":"LMP Palma","year":"2022","unstructured":"Palma LMP, Vaisbich-Guimaraes MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol. 2022;37:1967\u201380.","journal-title":"Pediatr Nephrol"},{"key":"545_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.ki.5001535","volume":"70","author":"HM Tsai","year":"2006","unstructured":"Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006;70:16\u201323.","journal-title":"Kidney Int"},{"key":"545_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","volume":"3","author":"XL Zheng","year":"2008","unstructured":"Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol. 2008;3:249\u201377.","journal-title":"Annu Rev Pathol"},{"key":"545_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101092","volume":"47","author":"C Weiss","year":"2024","unstructured":"Weiss C, Becker LL, Friese J, Blaschek A, Hahn A, Illsinger S, et al. Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study. Lancet Reg Health Eur. 2024;47:101092.","journal-title":"Lancet Reg Health Eur"},{"key":"545_CR26","doi-asserted-by":"crossref","unstructured":"Ruggiero R, Balzano N, Nicoletti MM, di Mauro G, Fraenza F, Campitiello MR, et al. Real-world safety data of the orphan drug onasemnogene abeparvovec (Zolgensma((R))) for the SMA rare disease: a pharmacovigilance study based on the EMA adverse event reporting system. Pharmaceuticals (Basel). 2024;17:394","DOI":"10.3390\/ph17030394"},{"key":"545_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","volume":"34","author":"MA Waldrop","year":"2024","unstructured":"Waldrop MA, Chagat S, Storey M, Meyer A, Iammarino M, Reash N, et al. Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio. Neuromuscul Disord. 2024;34:41\u20138.","journal-title":"Neuromuscul Disord"},{"key":"545_CR28","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1212\/WNL.0000000000200676","volume":"98","author":"K Yazaki","year":"2022","unstructured":"Yazaki K, Sakuma S, Hikita N, Fujimaru R, Hamazaki T. Child neurology: pathologically confirmed thrombotic microangiopathy caused by onasemnogene abeparvovec treatment for SMA. Neurology. 2022;98:808\u201313.","journal-title":"Neurology"},{"key":"545_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284\u201393.","journal-title":"Lancet Neurol"},{"key":"545_CR30","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832\u201341.","journal-title":"Lancet Neurol"},{"key":"545_CR31","doi-asserted-by":"crossref","unstructured":"Aigner C, Gaggl M, Kain R, Prohaszka Z, Garam N, Csuka D, et al. Sex differences in clinical presentation and outcomes among patients with complement-gene-variant-mediated thrombotic microangiopathy. J Clin Med. 2020;9:964","DOI":"10.3390\/jcm9040964"},{"key":"545_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03326-3","volume":"19","author":"I Desguerre","year":"2024","unstructured":"Desguerre I, Barrois R, Audic F, Barnerias C, Chabrol B, Davion JB, et al. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment. Orphanet J Rare Dis. 2024;19:344.","journal-title":"Orphanet J Rare Dis"},{"key":"545_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/JND-230122","volume":"11","author":"L Servais","year":"2024","unstructured":"Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, et al. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. J Neuromuscul Dis. 2024;11:425\u201342.","journal-title":"J Neuromuscul Dis"},{"key":"545_CR34","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","volume":"109","author":"M Othman","year":"2007","unstructured":"Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood. 2007;109:2832\u20139.","journal-title":"Blood"},{"key":"545_CR35","doi-asserted-by":"crossref","unstructured":"Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D\u2019Souza P, et al. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Invest. 2024;134.","DOI":"10.1172\/JCI173510"},{"key":"545_CR36","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1128\/JVI.00082-09","volume":"83","author":"J Tian","year":"2009","unstructured":"Tian J, Xu Z, Smith JS, Hofherr SE, Barry MA, Byrnes AP. Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J Virol. 2009;83:5648\u201358.","journal-title":"J Virol"},{"key":"545_CR37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/a-1538-4936","volume":"234","author":"D Witte","year":"2022","unstructured":"Witte D, Hartmann H, Drube J, Haffner D, Illsinger S. [Thrombotic microangiopathy (TMA) after gene replacemant therapy (GRT) due to spinal muscular atrophy: case summary and recommendations for treatment]. Klin Padiatr. 2022;234:42\u20137.","journal-title":"Klin Padiatr"},{"key":"545_CR38","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","volume":"33","author":"L Servais","year":"2023","unstructured":"Servais L, Horton R, Saade D, Bonnemann C, Muntoni F. st Ewsg. 261st ENMC International Workshop: management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands. Neuromuscul Disord. 2023;33:884\u201396.","journal-title":"Neuromuscul Disord"},{"key":"545_CR39","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2025","unstructured":"Greenberg B, Taylor M, Adler E, Colan S, Ricks D, Yarabe P, et al. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N Engl J Med. 2025;392:972\u201383.","journal-title":"N Engl J Med"},{"key":"545_CR40","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31:3123\u20136.","journal-title":"Mol Ther"},{"key":"545_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1089\/hum.2024.156","volume":"36","author":"GA Laforet","year":"2025","unstructured":"Laforet GA. Thrombotic microangiopathy associated with systemic adeno-associated virus gene transfer: review of reported cases. Hum Gene Ther. 2025;36:64\u201376.","journal-title":"Hum Gene Ther"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00545-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00545-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00545-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:38:41Z","timestamp":1766047121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00545-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00545-6","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that participated in the development and realization of the article. The authors agree with the time limit for publication. From this date, it becomes public responsibility for its contents. It was not obtained any funding agreements with agencies that may be interested in publishing this article. The article has not been and will not be submitted to other printed or electronic journals. We are also aware that all articles accepted for publication must be published with DOI (digital object identifier). The authors state that there was no conflict of interest during the performance and publication of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study received approval from the local ethics committee (63660222.5.0000.0068 CAPPESQ), and written informed consent was obtained from the patients\u2019 parents. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}